Presently, EGFR-TKI resistance in lung cancer arises through various mechanisms, including secondary mutations in EGFR (e.g., T790M), activation of alternative signaling pathways (e.g., MET, HER2), phenotypic transformation (small cell transformation). Here, ERBB2 is linked to lung cancer.